The MarketWatch News Department was not involved in the creation of this content. Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA ...
LA JOLLA, CA - GRI Bio, Inc. (NASDAQ:GRI) announced additional positive data from its Phase 2a clinical study of GRI-0621 in Idiopathic Pulmonary Fibrosis (IPF), showing the drug candidate’s potential ...
Interesting Engineering on MSN
First-ever experimental gene therapy seeks to restore vision by rejuvenating eye neurons
Life Biosciences is pushing cellular rejuvenation into the clinic with ER-100, an experimental gene ...
LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) --GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the“Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the ...
Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results